期刊
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
卷 11, 期 7, 页码 518-526出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.4251/wjgo.v11.i7.518
关键词
Gastroesophageal cancer; Chemotherapy; Biomarker; HER2
Key cytotoxic drugs of chemotherapy for gastroesophageal cancer indude fluoropyrimidine, platinum, taxanes and irinotecan. Concurrent chemoradiotherapy is one of the main treatment strategies, especially for esophageal cancer. As molecular target agents, the anti-HER2 antibody trastuzumab for HER2-positive gastric cancer and the anti-angiogenesis agent ramucirumab combined with paditaxel have been proven to improve the survival of gastric cancer patients. Recently, anti-PD-71 antibodies have become available as second- or later-line chemotherapy. Microsatellite instability is also useful as a biomarker to select patients suitable for immunotherapy. Furthermore, genome-wide analysis has improved our understanding of the biological features and molecular mechanisms of gastroesophageal cancer and will provide optimized treatment selection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据